206 related articles for article (PubMed ID: 29808463)
1. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Ascione A; De Luca M; Melazzini M; Montilla S; Trotta MP; Petta S; Puoti M; Sangiovanni V; Messina V; Bruno S; Izzi A; Villa E; Aghemo A; Zignego AL; Orlandini A; Fontanella L; Gasbarrini A; Marzioni M; Giannini EG; Craxì A;
Infection; 2018 Oct; 46(5):607-615. PubMed ID: 29808463
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Pessoa MG; Ramalho-Madruga JV; Alves K; Nunes EP; Cheinquer H; Brandão-Mello CE; Mendes-Correa MC; Ferraz ML; Ferreira PRA; Álvares-da-Silva MR; Coelho HS; Affonso-de-Araújo ES; Furtado J; Parana R; Silva G; Lari SA; Liu L; Tripathi R; Pilot-Matias T; Cohen DE; Shulman NS; Martinelli A
Ann Hepatol; 2018 Oct; 17(6):959-968. PubMed ID: 30600291
[TBL] [Abstract][Full Text] [Related]
3. Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.
Fuchs M; Monto A; Bräu N; Charafeddine M; Schmidt W; Kozal M; Naggie S; Cheung R; Schnell G; Yu Y; Richards K; Mullally V; Cohen DE; Toro D
J Med Virol; 2020 Dec; 92(12):3459-3464. PubMed ID: 31829433
[TBL] [Abstract][Full Text] [Related]
4. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
Ferenci P; Bourgeois S; Buggisch P; Norris S; Curescu M; Larrey D; Marra F; Kleine H; Dorr P; Charafeddine M; Crown E; Bondin M; Back D; Flisiak R
J Viral Hepat; 2019 Jun; 26(6):685-696. PubMed ID: 30739368
[TBL] [Abstract][Full Text] [Related]
5. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S; Marzioni M; Russo P; Aghemo A; Alberti A; Ascione A; Antinori A; Bruno R; Bruno S; Chirianni A; Gaeta GB; Giannini EG; Merli M; Messina V; Montilla S; Perno CF; Puoti M; Raimondo G; Rendina M; Silberstein FC; Villa E; Zignego AL; Pani L; Craxì A; ;
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):427-434. PubMed ID: 28497758
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
Dore GJ; Conway B; Luo Y; Janczewska E; Knysz B; Liu Y; Streinu-Cercel A; Caruntu FA; Curescu M; Skoien R; Ghesquiere W; Mazur W; Soza A; Fuster F; Greenbloom S; Motoc A; Arama V; Shaw D; Tornai I; Sasadeusz J; Dalgard O; Sullivan D; Liu X; Kapoor M; Campbell A; Podsadecki T
J Hepatol; 2016 Jan; 64(1):19-28. PubMed ID: 26321288
[TBL] [Abstract][Full Text] [Related]
7. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
Welzel TM; Hinrichsen H; Sarrazin C; Buggisch P; Baumgarten A; Christensen S; Berg T; Mauss S; Teuber G; Stein K; Deterding K; van Bömmel F; Heyne R; John C; Zimmermann T; Lutz T; Schott E; Hettinger J; Kleine H; König B; Hüppe D; Wedemeyer H
J Viral Hepat; 2017 Oct; 24(10):840-849. PubMed ID: 28342229
[TBL] [Abstract][Full Text] [Related]
8. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.
Aygen B; Demirtürk N; Yıldız O; Çelen MK; Çelik İ; Barut Ş; Ural O; Batırel A; Mıstık R; Şimşek F; Asan A; Ersöz G; Türker N; Bilgin H; Kınıklı S; Karakeçili F; Zararsız G; Turkish Society Of Clinical Microbiology And Infectious Diseases TSGFVHOT
Turk J Gastroenterol; 2020 Apr; 31(4):305-317. PubMed ID: 32412901
[TBL] [Abstract][Full Text] [Related]
9. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Feld JJ; Moreno C; Trinh R; Tam E; Bourgeois S; Horsmans Y; Elkhashab M; Bernstein DE; Younes Z; Reindollar RW; Larsen L; Fu B; Howieson K; Polepally AR; Pangerl A; Shulman NS; Poordad F
J Hepatol; 2016 Feb; 64(2):301-307. PubMed ID: 26476290
[TBL] [Abstract][Full Text] [Related]
10. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
Welzel TM; Asselah T; Dumas EO; Zeuzem S; Shaw D; Hazzan R; Forns X; Pilot-Matias T; Lu W; Cohen DE; Feld JJ
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):494-500. PubMed ID: 28416221
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
Shiffman ML; Rustgi V; Bennett M; Forns X; Asselah T; Planas Vila R; Liu L; Pedrosa M; Moller J; Reau N
Am J Gastroenterol; 2016 Jun; 111(6):845-51. PubMed ID: 27045929
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Poordad F; Sedghi S; Pockros PJ; Ravendhran N; Reindollar R; Lucey MR; Epstein M; Bank L; Bernstein D; Trinh R; Krishnan P; Polepally AR; Unnebrink K; Martinez M; Nelson DR
J Viral Hepat; 2019 Aug; 26(8):1027-1030. PubMed ID: 30980576
[TBL] [Abstract][Full Text] [Related]
14. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a.
Rosenthal P; Narkewicz MR; Yao BB; Jolley CD; Lobritto SJ; Wen J; Molleston JP; Hsu EK; Jonas MM; Zha J; Liu L; Leung DH
Adv Ther; 2020 Jul; 37(7):3299-3310. PubMed ID: 32451952
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
Liu CH; Liu CJ; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2018 Mar; 33(3):710-717. PubMed ID: 28762541
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.
Chamorro-de-Vega E; Gimenez-Manzorro A; Rodriguez-Gonzalez CG; Escudero-Vilaplana V; Collado Borrell R; Ibañez-Garcia S; Lallana Sainz E; Lobato Matilla E; Lorenzo-Pinto A; Manrique-Rodriguez S; Fernandez-Llamazares CM; Marzal-Alfaro M; Ribed A; Romero Jimenez RM; Sarobe Gonzalez C; Herranz A; Sanjurjo M
Ann Pharmacother; 2016 Nov; 50(11):901-908. PubMed ID: 27422641
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of paritaprevir/ritonavir/ombitasvir combined with dasabuvir in non-cirrhotic Asian adult patients with newly diagnosed and treated chronic HCV genotype 1b infection: a randomized, double-blind, placebo-controlled study - China data].
Wei L; Cheng J; Luo J; Li ZP; Duan JL; Hou JD; Jia MX; Zhang Y; Huang Q; Xie GJ; Wang DL; Yang W; Zhao CY; Zhao G; Tang SM; Lin GZ; Gong JJ; Niu ZL; Gao JF; Sarah KB; Linda F; Niloufar M; Wang Y; Wang J
Zhonghua Gan Zang Bing Za Zhi; 2018 May; 26(5):359-364. PubMed ID: 29996204
[No Abstract] [Full Text] [Related]
18. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
19. Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
Chan HL; Tsang OT; Hui YT; Fung J; Lui GC; Lai CL; Wong GL; Chan KH; But DY; Lai MS; Lao WC; Chan CK; Lam YS; Seto WK; Li C; Yuen MF; Wong VW
J Gastroenterol Hepatol; 2017 Jun; 32(6):1230-1233. PubMed ID: 27869328
[TBL] [Abstract][Full Text] [Related]
20. High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
Sanai FM; Alghamdi AS; Afghani AA; Alswat K; AlZanbagi A; Alghamdi MN; AlMousa A; Aseeri M; Assiri AM; Babatin MA
Liver Int; 2018 Aug; 38(8):1395-1401. PubMed ID: 29288514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
